Vyome Holdings, Inc (HIND) stock

HINDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30

$1.58−0.05 (-3.07%)

Close on Nov 13, 2026Market cap $11.09MP/E –Yield –

Vyome ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Vyome's ebitda for the twelve months ending Sep 30, 2026 was -$4.36M. For fiscal 2025 it was -$10.44M. The highest annual figure on record is -$988.99K in fiscal 2024.

Annual ebitda

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$10.44M	–
FY2024	Dec 31, 2024	-$988.99K	–
FY2020	Dec 31, 2020	-$12.12M	–
FY2019	Dec 31, 2019	-$22.75M	–
FY2017	Dec 31, 2017	-$34.06M	–
FY2016	Dec 31, 2016	-$19.31M	–
FY2015	Dec 31, 2015	-$14.77M	–
FY2014	Dec 31, 2014	-$9.67M	–

Quarterly ebitda

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$1.02M	–
Q2 FY2026	Jun 30, 2026	-$859.96K	–
Q1 FY2026	Mar 31, 2026	-$1.13M	–
Q4 FY2025	Dec 31, 2025	-$1.35M	–
Q3 FY2025	Sep 30, 2025	-$8.57M	–
Q2 FY2025	Jun 30, 2025	-$321.22K	–
Q1 FY2025	Mar 31, 2025	-$195.48K	–
Q4 FY2024	Dec 31, 2024	-$252.14K	–
Q3 FY2024	Sep 30, 2024	-$276.55K	–
Q1 FY2021	Mar 31, 2021	-$2.19M	–
Q4 FY2020	Dec 31, 2020	-$3.12M	–
Q3 FY2020	Sep 30, 2020	-$2.07M	–
Q2 FY2020	Jun 30, 2020	-$2.90M	–
Q1 FY2020	Mar 31, 2020	-$4.81M	–
Q4 FY2019	Dec 31, 2019	-$4.86M	–
Q3 FY2019	Sep 30, 2019	-$3.64M	–
Q2 FY2019	Jun 30, 2019	-$6.31M	–
Q1 FY2019	Mar 31, 2019	-$7.95M	–
Q3 FY2018	Sep 30, 2018	-$6.54M	–
Q2 FY2018	Jun 30, 2018	-$9.40M	–
Q1 FY2018	Mar 31, 2018	-$11.94M	–
Q4 FY2017	Dec 31, 2017	-$9.81M	–
Q3 FY2017	Sep 30, 2017	-$9.04M	–
Q2 FY2017	Jun 30, 2017	-$7.54M	–
Q1 FY2017	Mar 31, 2017	-$7.63M	–
Q4 FY2016	Dec 31, 2016	-$7.48M	–